Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 10.5 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), a shelf registration filed Jan 12, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$23.2MCash on Hand
10.5mo Cash Runway
10%Short Interest
$21.2Analyst Target (5)
Follow CING by emailGet an email when CING reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CING, unsubscribe in one click. Privacy
📣 What CING Says Is Next
by January 2027 · ““With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner,” stated Cingulate Chairman and CEO Shane J.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · “The Company expects current cash on hand will satisfy its capital needs into late fourth quarter of 2026 under the current business plan, which primarily includes activities related to seeking regulatory approval for CTx-1301 and pre-commercialization efforts for CTx-1301.”
Company press release, Mar 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Financing Amended its At-the-Market agreement to add Maxim Group as a sales agent alongside A.G.P., keeping the $100,000,000 program. Reported Q3 cash of $23.2 million, runway into mid-2027, and NDA resubmission for CTx-1301 expected December 2026 to January 2027. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Financing Cingulate amended its March 24, 2026 prospectus supplement for an at-the-market offering of up to $100,000,000 of common stock. Maxim Group LLC was added as an additional sales agent alongside A.G.P./Alliance Global Partners. Form 424B3 · SEC filing
Nov 10, 2026 ·
Regulatory Cingulate said it expects to resubmit the CTx-1301 NDA between December 2026 and January 2027, following a June 1, 2026 complete response letter that cited CMC requests only. A commercial launch could start in Q3 2027 if approved, with no assurance of timing or approval. Form 8-K · SEC filing · Press release
Oct 2, 2026 ·
Leadership Cingulate extended the trial period for Matthew N. Brams, Executive Vice President and Chief Medical Officer, from September 30, 2026 to December 31, 2026, under Amendment No. 2 to his employment agreement with its subsidiary. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Cingulate reported Q2 2026 cash of $28.4 million, runway into mid-2027, and a net loss of $5.9 million, with SG&A up 101.5% to $3.9 million as it builds commercial readiness for CTx-1301 after an FDA complete response letter. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
2026-11-10 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
2026-06-02 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
2026-05-14 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
2026-03-18 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
2026-02-17 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
2025-11-13 · PDUFA date · PDUFA Date Mentioned in 8-K Filing Disclosed by the company in an SEC filing
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CING holds $23.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.6M/quarter from operations,
an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 10 months +30
ATM program on file since Jan 2026 +15
Shelf registration (S-3, Jan 2026) +10
Going-concern doubt in the latest 10-Q +15These uncertainties raise substantial doubt about our ability to continue as a going concern for one year after the issuance date of our financial statements.10-Q, Nov 2026
Share count 14,541,826 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-09-30 filed 2026-10-02
Silva Raul R.
Option award (A)
4,293
–
–
2026-07-16 filed 2026-07-20
Schaffer Shane J.
Option award (A)
197,650
–
–
2026-07-16 filed 2026-07-20
Silva Raul R.
Option award (A)
53,600
–
–
2026-07-16 filed 2026-07-20
Silva Raul R.
Option award (A)
26,400
–
–
2026-07-16 filed 2026-07-20
Werth Peter J.
Option award (A)
20,000
–
–
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full CING picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CING and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.